Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist

Journal of Hypertension

Volumn 13, Issue 12, 1995, Pages 1842-1846

  Petrie, John R ^a   Glen, Stephen K ^a   MacMahon, Mark ^b   Crome, Renata ^c   Meredith, Peter A ^a   Elliott, Henry L ^a   Reid, John L ^a  

^a WESTERN INFIRMARY   (United Kingdom)

^b Chiltern International Ltd   (United Kingdom)

^c ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Atrioventricular conduction; Blood pressure; Calcium antagonists; Dromotropic effects; Hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; DILTIAZEM; DRUG METABOLITE; MIBEFRADIL; NORVERAPAMIL; VERAPAMIL;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; DYSPEPSIA; ELECTROCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HEART BLOCK; HEART CONDUCTION; HEART PALPITATION; HEART RATE; HEARTBURN; HEMODYNAMICS; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

EID: 0029609806     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Schmitt R, Kleinbloesem CH, Belz CG, Schroeter V, Feifel U, Pozenel H, et al.: Haemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther 1992, 52:314-323.
2. Mishra SK, Hermsmeyer K: Selective inhibition of T-type calcium2+ channels by Ro 40-5967. Circ Res 1994, 75:144-148.
3. Matthews JNS, Altman DG, Campbell MJ, Royston P: Analysis of serial measures in medical research. BMJ 1990, 300:230-235.